Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Athanasios Fountas, Leonidas Nikolaos Diamantopoulos, Agathocles Tsatsoulis
Trends in Endocrinology and Metabolism (2015) Vol. 26, Iss. 11, pp. 643-656
Closed Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 117
Ageing – Oxidative stress, PTMs and disease
Thomas Ebert, Tran Uyen Ngoc, Leon J. Schurgers, et al.
Molecular Aspects of Medicine (2022) Vol. 86, pp. 101099-101099
Open Access | Times Cited: 72
Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes
Shuhei Morita, S. Armando Villalta, Hannah C. Feldman, et al.
Cell Metabolism (2017) Vol. 25, Iss. 5, pp. 1207-1207
Open Access | Times Cited: 157
Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes
Shuhei Morita, S. Armando Villalta, Hannah C. Feldman, et al.
Cell Metabolism (2017) Vol. 25, Iss. 4, pp. 883-897.e8
Open Access | Times Cited: 157
Enzymes inhibitors from natural sources with antidiabetic activity: A review
Fiaz Alam, Zainab Shafique, Sayyeda Tayyeba Amjad, et al.
Phytotherapy Research (2018) Vol. 33, Iss. 1, pp. 41-54
Open Access | Times Cited: 142
Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives
Hassan Rasouli, Reza Yarani, Flemming Pociot, et al.
Pharmacological Research (2020) Vol. 155, pp. 104723-104723
Closed Access | Times Cited: 100
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen E. Gitelman, Brian N. Bundy, Ele Ferrannini, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 502-514
Open Access | Times Cited: 91
Neratinib protects pancreatic beta cells in diabetes
Amin Ardestani, Sijia Li, Karthika Annamalai, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 56
Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice
Sorim Choung, Ji Min Kim, Kyong Hye Joung, et al.
PLoS ONE (2019) Vol. 14, Iss. 2, pp. e0210828-e0210828
Open Access | Times Cited: 55
Synthesis, structure of the N-(Alkyl/Arylsulfonyl) substituted 5-(Bromo/Iodo)-3-methylindazoles and bioactivity screening against some of the biochemical targets linked to type 2 diabetes mellitus
Malose J. Mphahlele, Nontokozo M. Magwaza, Garland K. More, et al.
Journal of Molecular Structure (2024) Vol. 1312, pp. 138636-138636
Open Access | Times Cited: 6
Epidermal Growth Factor Receptor Signaling Disruption by Endocrine and Metabolic Disrupting Chemicals
Josiah Hardesty, Laila Al‐Eryani, Banrida Wahlang, et al.
Toxicological Sciences (2018) Vol. 162, Iss. 2, pp. 622-634
Open Access | Times Cited: 48
Emerging roles of the αC‐β4 loop in protein kinase structure, function, evolution, and disease
Wayland Yeung, Zheng Ruan, Natarajan Kannan
IUBMB Life (2020) Vol. 72, Iss. 6, pp. 1189-1202
Open Access | Times Cited: 39
Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases
Rong Tang, Wallace Y. Langdon, Jian Zhang
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 27
Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
Takudzwa Mugiya, Mamosheledi Mothibe, Andile Khathi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations
Hywel D. Williams, Leigh Ford, Sifei Han, et al.
Molecular Pharmaceutics (2018) Vol. 15, Iss. 12, pp. 5678-5696
Open Access | Times Cited: 45
Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
Natia Peradze, Olivia M. Farr, Nikolaos Perakakis, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 42
The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
Bara A. Shraim, Moaz O. Moursi, Ibrahim F. Benter, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 31
Promotion of beta cell proliferation through DYRK kinase inhibition using the marine natural product breitfussin C
Sara Ullsten, Kine Ø. Hansen, Guillaume A. Petit, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia
Brittany M. Duggan, Kevin P. Foley, Brandyn D. Henriksbo, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 36
Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
Lili Sheng, George Bayliss, Shougang Zhuang
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 26
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Nidhi Mehra, Armon Varmeziar, Xinyu Chen, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4686-4686
Open Access | Times Cited: 18
The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy
Yunfei Yin, Mingyue Tan, Lianhua Han, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 5, pp. 1956-1975
Open Access | Times Cited: 9
Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimer’s Disease and Brain Insulin Resistance, and Its Relation to Cancer
M. Murat Köseoğlu, Andrés Norambuena, Elizabeth R. Sharlow, et al.
Journal of Alzheimer s Disease (2018) Vol. 67, Iss. 1, pp. 1-11
Open Access | Times Cited: 30
Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update
Zhichao Zhou, Takayuki Matsumoto, Vera Jankowski, et al.
Pharmacological Research (2018) Vol. 141, pp. 32-45
Open Access | Times Cited: 28
<p>Galangin Inhibits LPS-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent AP-1 and FoxO1 Activation in Rat Brain Astrocytes</p>
Chien-Chung Yang, Li‐Der Hsiao, Chuen‐Mao Yang
Journal of Inflammation Research (2020) Vol. Volume 13, pp. 945-960
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top